In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

Explore GISTs, rare GI tumors. Discover key details on genetic causes, diagnostic methods, and cutting-edge treatment ...

CNW/ -- (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to jointly announce ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness ...

Researchers have unlocked a powerful new way to fight solid tumors using smart immune cells that stay active longer and hit harder. Called EchoBack CAR T-cells, these new cancer-fighting tools ...

Declining cytoreductive surgery in advanced EOC is associated with significantly poorer survival outcomes compared to those who undergo the procedure. Sociodemographic factors, including race, age ...

Department of Orthopaedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China ...

BELLA is a single-arm, open-label trial with a planned enrollment of 90 women with recurrent, platinum-resistant ovarian cancer at approximately 50 sites in North America, Europe and Asia-Pacific.

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, according to a study published online April 1 in JAMA Network Open.

in recurrent ovarian clear cell carcinoma. 3 The study, led by investigators at The University of Texas MD Anderson Cancer Center, has an estimated enrollment of 21 patients. Estimated OS rates at 6 ...